tbuckley/cabot-search huggingface dataset:
Time of Origin and Environmental Drivers of Leukemia Immune Escape after Transplantation
Authors: Cristina Toffalori, Riccardo Bergamin, Alice Antonello, Anna Francesca Tortorelli, Giorgio Orofino, Matteo Cristante, Lucrezia Della Volpe, Salvatore Milite, Nicola Calonaci, Giorgia Gandolfi, Aurora Maurizio, Raffaella Greco, Gabriele Bucci, Dejan Lazarevic, Raffaella Di Micco, Giovanni Tonon, Fabio Ciceri, Giulio Caravagna, Luca Vago
Journal: Blood (2023)
<i>Mutation of Epigenetic Regulators at Diagnosis Is an Independent Predictor of Tyrosine Kinase Inhibitor Treatment Failure: A Report from the Residiag Study</i>
Authors: Hippolyte Guerineau, Jean-Michel Cayuela, Stéphanie Dulucq, Violaine Tran Quang, Sihem Tarfi, Quentin Barathon, Corine Joy, Orianne Wagner-Ballon, Stéphane Morisset, Franck E. Nicolini, Lydia Roy, Sébastien Maury, Gabriel Etienne, Delphine Rea, Ivan Sloma
Journal: Blood (2023)
The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder
Authors: Evelyn H. Orlando, Patrick Gould, Brian Cuzzo, Maegan Ford, Yuxuan Chen, Alexander Sanjurjo, Benjamin May, Demetra Tsapepas, Rebecca J. Leeman-Neill, Govind Bhagat, Geoffrey Dube, Heather Morris, Selim Arcasoy, Farhana Latif, Mercedes Martinez, Marcus Pereira, Andrew H. Lipsky, Ahmed Sawas, Ran Reshef, Barbara Pro, Hua-Jay J. Cherng, Jennifer E. Amengual
Journal: Blood (2023)
Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission
Authors: Mazyar Shadman, Kwang Wooahn, Manmeet Kaur, Mohamed A. Kharfan-Dabaja, Alex F. Herrera, Craig S Sauter, Mehdi Hamadani
Journal: Blood (2023)
Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
Authors: Emmanuel Almanza Huante, Alex Bataller, Danielle E. Hammond, Kelly S. Chien, Courtney D. DiNardo, Nicholas J. Short, Abhishek Maiti, Guillermo Montalban-Bravo, Farhad Ravandi, Guillermo Garcia-Manero, Tapan M. Kadia
Journal: Blood (2023)
Decider-2: Prospective Randomized Multicenter Phase III Trial of Decitabine and Venetoclax Administered in Combination with All- <i>Trans</i> Retinoic Acid (ATRA) or Placebo in Patients with Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy
Authors: Michael Lübbert, Claudia Schmoor, Olga Grishina, Christoph Rummelt, Johanna Thomas, Michael Heuser, Konstanze Döhner, Hartmut Döhner, Heiko Becker, Ralph Wäsch
Journal: Blood (2023)
Are perinatal antibiotics responsible for atopic dermatitis? The debate rages on
Authors: JiaDe Yu
Journal: British Journal of Dermatology (2023)

Journal Article Corrected proof Are perinatal antibiotics responsible for atopic dermatitis? The debate rages on Get access JiaDe Yu JiaDe Yu Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA Email: Jiade.yu@mgh.harvard.edu https://orcid.org/0000-0002-0874-3170 Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad477, https://doi.org/10.1093/bjd/ljad477 Published: 30 November 2023 Article history Received: 22 November 2023 Accepted: 24 November 2023 Published: 30 November 2023 Corrected and typeset: 23 January 2024
Phase I Open-Label Single-Arm Study of Sscart-19 in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in China
Authors: Liqing Kang, Shengli Xue, Xiaowen Tang, Xiaoyan Lou, Chongsheng Qian, Wenjie Gong, Mingzhu Xu, Haixia Zhou, Zhen Yao, Wei Wang, Minghao Li, Nan Xu, Zhou Yu, Suning Chen, Huiying Qiu, Haiping Dai, Yang Xu, Depei Wu, Lei Yu
Journal: Blood (2023)
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators
Authors: Merijn C F Mulders, Wouter W de Herder, Johannes Hofland
Journal: Endocrine Reviews (2023)

Abstract Carcinoid syndrome (CS) is a debilitating disease that affects approximately 20% of patients with neuroendocrine neoplasms (NEN). Due to the increasing incidence and improved overall survival of patients with NEN over recent decades, patients are increasingly suffering from chronic and refractory CS symptoms. At present, symptom control is hampered by an incomplete understanding of the pathophysiology of this syndrome. This systematic review is the first to critically appraise the available evidence for the various hormonal mediators considered to play a causative role in CS. Overall, evidence for the putative mediators of CS was scarce and often of poor quality. Based on the available literature, data are only sufficient to agree on the role of serotonin as a mediator of CS-associated diarrhea and fibrosis. A direct role for tachykinins and an indirect role of catecholamines in the pathogenesis of CS is suggested by several studies. Currently, there is insufficient evidence to link histamine, bradykinin, kallikrein, prostaglandins, or motilin to CS. To summarize, available literature only sufficiently appoints serotonin and suggests a role for tachykinins and catecholamines as mediators of CS, with insufficient evidence for other putative mediators. Descriptions of CS should be revised to focus on these proven hormonal associations to be more accurate, and further research is needed into other potential mediators.
Mortality in patients with psoriatic arthritis in Sweden: a nationwide, population-based cohort study
Authors: Sofia Exarchou, Daniela Di Giuseppe, Eva Klingberg, Valgerdur Sigurdardottir, Sara Wedrén, Ulf Lindström, Carl Turesson, Lennart T H Jacobsson, Johan Askling, Johan K Wallman
Journal: Annals of the Rheumatic Diseases (2023)

Objectives To compare all-cause mortality and causes of death between patients with psoriatic arthritis (PsA) and the general population in Sweden. Methods Adults with at least one main PsA diagnosis (International Classification of Diseases-10: L40.5/M07.0–M07.3) from outpatient rheumatology/internal medicine departments 2001–2017 were identified from the National Patient Register. Each case was matched to five population comparator-subjects on sex/county/age at the case’s first arthritis diagnosis. Follow-up ran from 1 January 2007, or from first PsA diagnosis thereafter, until death, emigration or 31 December 2018. Mortality was assessed overall, and stratified by sex and duration since diagnosis (diagnosis before/after 1 January 2007), using matched Cox proportional hazard regression (excluding/including adjustments for comorbidity) or Breslow test, as appropriate. Incidence rate ratios (IRR) of death, overall and stratified by sex/duration since diagnosis/age, as well as causes of death in PsA cases and comparator-subjects were also described. Results All-cause mortality was elevated in PsA (HR: 1.11 (95% CI: 1.07 to 1.16); IRR: 1.18 (95% CI: 1.13 to 1.22)), mainly driven by increased risks in women (HR: 1.23 (95% CI: 1.16 to 1.30)) and cases with longer time since diagnosis (HR: 1.18 (95% CI: 1.12 to 1.25)). IRR of death were significantly increased for all ages except below 40 years, with the numerically highest point-estimates for ages 40–59 years. When adjusted for comorbidity, however, the elevated mortality risk in PsA disappeared. Causes of death were similar among PsA cases/comparator-subjects, with cardiovascular disease and malignancy as the leading causes. Conclusions Mortality risk in PsA in Sweden was about 10% higher than in the general population, driven by excess comorbidity and with increased risks mainly in women and patients with longer disease duration.
Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group
Authors: Kresten Krarup Keller, Chetan B Mukhtyar, Andreas Wiggers Nielsen, Andrea Katharina Hemmig, Sarah Louise Mackie, Sebastian Eduardo Sattui, Ellen-Margrethe Hauge, Anisha Dua, Toby Helliwell, Lorna Neill, Daniel Blockmans, Valérie Devauchelle-Pensec, Eric Hayes, Annett Jansen Venneboer, Sara Monti, Cristina Ponte, Eugenio De Miguel, Mark Matza, Kenneth J Warrington, Kevin Byram, Kinanah Yaseen, Christine Peoples, Michael Putman, Lindsay Lally, Michael Finikiotis, Simone Appenzeller, Ugo Caramori, Carlos Enrique Toro-Gutiérrez, Elisabeth Backhouse, María Camila Guerrero Oviedo, Victor Román Pimentel-Quiroz, Helen Isobel Keen, Claire Elizabeth Owen, Thomas Daikeler, Annette de Thurah, Wolfgang A Schmidt, Elisabeth Brouwer, Christian Dejaco
Journal: Annals of the Rheumatic Diseases (2023)

To develop international consensus-based recommendations for early referral of individuals with suspected polymyalgia rheumatica (PMR).
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Authors: Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon
Journal: Eurosurveillance (2023)

Background Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. Aim We assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. Methods We performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. Results We included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. Conclusions Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Assessing the health burden of vaccine-preventable infections in European adults: challenges and opportunities translated into action
Authors: Jade Pattyn, Paolo Bonanni
Journal: Eurosurveillance (2023)

Preview this article: Assessing the health burden of vaccine-preventable infections in European adults: challenges and opportunities translated into action, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/28/48/eurosurv-28-48-5-1.gif
Hybrid-hybrid correction of errors in long reads with HERO
Authors: Xiongbin Kang, Jialu Xu, Xiao Luo, Alexander Schönhuth
Journal: Genome biology (2023)

Abstract Although generally superior, hybrid approaches for correcting errors in third-generation sequencing (TGS) reads, using next-generation sequencing (NGS) reads, mistake haplotype-specific variants for errors in polyploid and mixed samples. We suggest HERO, as the first “hybrid-hybrid” approach, to make use of both de Bruijn graphs and overlap graphs for optimal catering to the particular strengths of NGS and TGS reads. Extensive benchmarking experiments demonstrate that HERO improves indel and mismatch error rates by on average 65% (27 $$\sim$$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mo>∼</mml:mo> </mml:math> 95%) and 20% (4 $$\sim$$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mo>∼</mml:mo> </mml:math> 61%). Using HERO prior to genome assembly significantly improves the assemblies in the majority of the relevant categories.
Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the <scp>EMPEROR</scp> trials
Authors: João Pedro Ferreira, Javed Butler, Stefan D. Anker, James L. Januzzi, Marina Panova‐Noeva, Alexander L. Reese‐Petersen, Naveed Sattar, Elke Schueler, Stuart J. Pocock, Gerasimos Filippatos, Milton Packer, Mikhail Sumin, Faiez Zannad
Journal: European Journal of Heart Failure (2023)

Extracellular matrix remodelling is one of the key pathways involved in heart failure (HF) progression. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) may have a role in attenuating myocardial fibrosis. The impact of SGLT2i on blood markers of collagen turnover in humans is not fully elucidated. This study aimed to investigate the effect of empagliflozin on serum markers of collagen turnover in patients enrolled in the EMPEROR-Preserved and EMPEROR-Reduced trials.
Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer
Authors: Yaniv Kazansky, Alex Kentsis
Journal: Cancer Research (2023)

Abstract NUT carcinoma (NC) is one of the most common types of undifferentiated carcinomas affecting young adults with a dismal prognosis. NUT carcinomas often involve chromosomal translocations, leading to the production of BRD4-NUT fusion protein that generates large domains of hyperactive chromatin and activates oncogenic gene expression. Bromodomain and extraterminal domain (BET) bromodomain inhibitors offer a direct means to block BRD4-mediated gene activation but have shown limited clinical efficacy in patients. In this issue of Cancer Research, Huang and colleagues report an unexpected discovery of a synthetic lethal NC dependency on Polycomb repressive complex 2 (PRC2)–mediated gene repression, including EZH2, the catalytic subunit of PRC2. EZH2 is highly expressed in NC patient tumors and a specific inhibitor of its methyltransferase activity, tazemetostat, exhibits potent antitumor cell activity. While the repressed and activated chromatin domains in NC cells are distinct, the resultant gene expression changes exhibit convergent features, including dysregulation of CDKN2A and the E2F-RB1 axis. As a result, combined treatment of NC tumors with tazemetostat and the BET inhibitor mivebresib produces marked antitumor therapeutic synergy in vitro and in vivo, associated with enhanced suppression of RB1 function through convergent remodeling of NC gene expression. This study advances epigenetic cooperativity as a distinct mode of gene expression dysregulation in NC and nominates a compelling combination epigenetic strategy for investigation in clinical trials for patients. See related article by Huang et al., p. 3956
Mesenchymal stem cell-derived apoptotic bodies alleviate alveolar bone destruction by regulating osteoclast differentiation and function
Authors: Xiaoyan Li, Yiyang Jiang, Xu Liu, Jingfei Fu, Juan Du, Zhenhua Luo, Junji Xu, Ujjal Kumar Bhawal, Yi Liu, Lijia Guo
Journal: International Journal of Oral Science (2023)

Periodontitis is caused by overactive osteoclast activity that results in the loss of periodontal supporting tissue and mesenchymal stem cells (MSCs) are essential for periodontal regeneration. However, the hypoxic periodontal microenvironment during periodontitis induces the apoptosis of MSCs. Apoptotic bodies (ABs) are the major product of apoptotic cells and have been attracting increased attention as potential mediators for periodontitis treatment, thus we investigated the effects of ABs derived from MSCs on periodontitis. MSCs were derived from bone marrows of mice and were cultured under hypoxic conditions for 72 h, after which ABs were isolated from the culture supernatant using a multi-filtration system. The results demonstrate that ABs derived from MSCs inhibited osteoclast differentiation and alveolar bone resorption. miRNA array analysis showed that miR-223-3p is highly enriched in those ABs and is critical for their therapeutic effects. Targetscan and luciferase activity results confirmed that Itgb1 is targeted by miR-223-3p, which interferes with the function of osteoclasts. Additionally, DC-STAMP is a key regulator that mediates membrane infusion. ABs and pre-osteoclasts expressed high levels of DC-STAMP on their membranes, which mediates the engulfment of ABs by pre-osteoclasts. ABs with knock-down of DC-STAMP failed to be engulfed by pre-osteoclasts. Collectively, MSC-derived ABs are targeted to be engulfed by pre-osteoclasts via DC-STAMP, which rescued alveolar bone loss by transferring miR-223-3p to osteoclasts, which in turn led to the attenuation of their differentiation and bone resorption. These results suggest that MSC-derived ABs are promising therapeutic agents for the treatment of periodontitis.
Determining hemodilution in diagnostic bone marrow aspirated samples in plasma cell disorders by next-generation flow cytometry: Proposal for a bone marrow quality index
Authors: Jón Þórir Óskarsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Thor Aspelund, Steinar Bragi Gunnarsson, Guðlaug Katrín Hákonardóttir, Guðrún Ásta Sigurðardóttir, Ásdís Rósa Þórðardóttir, Gauti Kjartan Gíslason, Andri Ólafsson, Jón Kristinn Sigurðsson, Elías Eyþórsson, Ásbjörn Jónsson, Brynjar Viðarsson, Páll Torfi Önundarson, Bjarni A. Agnarsson, Róbert Pálmason, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Stephen Harding, Juan Flores-Montero, Alberto Orfao, Brian G. M. Durie, Thorvardur Jon Love, Sigurdur Yngvi Kristinsson
Journal: Blood Cancer Journal (2023)

Abstract Hemodilution of bone marrow (BM) aspirates is a limitation of multiparameter flow cytometry (MFC) in plasma cell disorders. There is a need for a validated approach for assessing sample quality and the distribution of non-plasma cell BM populations by MFC could provide a solution. We evaluated BM-associated cell populations, assessed by next-generation flow cytometry (NGF) and white blood cell (WBC) count in 351 BM aspirated samples from 219 participants with plasma cell disorders in the Iceland Screens, Treats, or Prevents MM study (iStopMM), as markers of hemodilution by their discriminatory ability between first and (generally more hemodiluted) second pull BM aspirated samples. The most discriminating markers were used to derive a novel BM quality index (BMQI). Nucleated red blood cells and myeloid precursors provided the greatest discriminatory ability between first vs second pull samples (area under the curve (AUC): 0.87 and 0.85, respectively), significantly better than B cell precursors (AUC = 0.64; p &lt; 0.001), mast cells (AUC = 0.65; p &lt; 0.001), and the BM WBC count (AUC = 0.77; p &lt; 0.05). We generated a novel BMQI that is intrinsic to current NGF protocols, for evaluating quality of diagnostic BM samples and suggest the use of a BMQI scoring system for interpreting results and guiding appropriate actions.
Gut microbiota induces weight gain and inflammation in the gut and adipose tissue independent of manipulations in diet, genetics, and immune development
Authors: Devesha H. Kulkarni, Brigida Rusconi, Alexandria N. Floyd, Elisabeth L. Joyce, Khushi B. Talati, Hrishi Kousik, Dereck Alleyne, Dalia L. Harris, Lorena Garnica, Ryan McDonough, Shay S. Bidani, Hrishikesh S. Kulkarni, Elizabeth P. Newberry, Keely G. McDonald, Rodney D. Newberry
Journal: Gut Microbes (2023)

Obesity and the metabolic syndrome are complex disorders resulting from multiple factors including genetics, diet, activity, inflammation, and gut microbes. Animal studies have identified roles for each of these, however the contribution(s) specifically attributed to the gut microbiota remain unclear, as studies have used combinations of genetically altered mice, high fat diet, and/or colonization of germ-free mice, which have an underdeveloped immune system. We investigated the role(s) of the gut microbiota driving obesity and inflammation independent of manipulations in diet and genetics in mice with fully developed immune systems. We demonstrate that the human obese gut microbiota alone was sufficient to drive weight gain, systemic, adipose tissue, and intestinal inflammation, but did not promote intestinal barrier leak. The obese microbiota induced gene expression promoting caloric uptake/harvest but was less effective at inducing genes associated with mucosal immune responses. Thus, the obese gut microbiota is sufficient to induce weight gain and inflammation.
Selected Articles from This Issue
Journal: Clinical Cancer Research (2023)

Highlights| December 01 2023 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2023 American Association for Cancer Research2023American Association for Cancer Research Clin Cancer Res (2023) 29 (23): 4699. https://doi.org/10.1158/1078-0432.CCR-29-23-HI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record December 1 2023 Citation Selected Articles from This Issue. Clin Cancer Res 1 December 2023; 29 (23): 4699. https://doi.org/10.1158/1078-0432.CCR-29-23-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Pediatric glioma patients typically respond poorly to immune checkpoint inhibitors (ICI) due to an immune suppressive environment, low tumor mutational burden (TMB), low MHC expression, and heterogeneity of mismatch repair deficient (MMRD) cells within glioma tumors. However, a subset of MMRD-driven hypermutated pediatric glioma patients may benefit from ICI therapy. In this open-label, single-arm pilot study, Das and colleagues assessed the safety and efficacy of the anti-PD-1 immunotherapeutic nivolumab in pediatric patients with relapsed/refractory cancers with elevated TMB and/or MMRD. The authors found that nivolumab was well tolerated, with most patients experiencing grade ≤ 2 treatment-related adverse events (TRAE) and only one patient discontinuing treatment due to grade 3 pancreatitis. A delayed immune response led to an initial overall response rate (ORR) of 20%, however the ORR increased to 50% after the trial ended, with 30% of patients achieving complete response and 20% of patients demonstrating partial response. At a... You do not currently have access to this content.
Molecular mechanisms of cellular metabolic homeostasis in stem cells
Authors: Xiaoyu Li, Ou Jiang, Songlin Wang
Journal: International Journal of Oral Science (2023)

Abstract Many tissues and organ systems have intrinsic regeneration capabilities that are largely driven and maintained by tissue-resident stem cell populations. In recent years, growing evidence has demonstrated that cellular metabolic homeostasis plays a central role in mediating stem cell fate, tissue regeneration, and homeostasis. Thus, a thorough understanding of the mechanisms that regulate metabolic homeostasis in stem cells may contribute to our knowledge on how tissue homeostasis is maintained and provide novel insights for disease management. In this review, we summarize the known relationship between the regulation of metabolic homeostasis and molecular pathways in stem cells. We also discuss potential targets of metabolic homeostasis in disease therapy and describe the current limitations and future directions in the development of these novel therapeutic targets.